Elemene liposomes for advanced endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called elemene liposomes, given as an injection and an oral liquid, for people with advanced or recurrent endometrial cancer who have not had other cancer treatments recently. The goal is to see if it can help shrink or control the cancer with fewer side effects than traditional chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of endometrial cancer (including certain types like endometrioid, serous, clear cell, etc.)
- Your cancer must be either advanced (Stage III or IV) or have come back after treatment (recurrent)
- You cannot have had chemotherapy, immunotherapy, or radiation in the last 6 months
- You must be able to do daily activities with little or no help (ECOG score 0 or 1)
- Your blood counts, kidney, and liver function must be within normal limits
- If you are able to become pregnant, you must have a negative pregnancy test and not be breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two medications (elacestrant and everolimus) to treat advanced or recurrent endometrial cancer that has hormone receptors. The drugs work by blocking cancer cell growth pathways, and this study explores whether using them together is safe and effective for patients whose cancer has progressed despite previous treatment.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a combination of the immunotherapy drug tislelizumab (which helps your immune system fight cancer) with standard chemotherapy, given before surgery for advanced endometrial cancer. The goal is to shrink the tumor and improve treatment outcomes.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
Hear when a new Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.